1.
Strategies for containing an emerging influenza pandemic in Southeast Asia
by Fraser, Christophe
Nature, 2005-09-08, Vol.437 (7056), p.209-214
2.
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
by Koh, Christopher, Dr
The Lancet infectious diseases, 2015, Vol.15 (10), p.1167-1174
3.
Hepatitis B virus infection
by Liaw, Yun-Fan, Prof
The Lancet (British edition), 2009, Vol.373 (9663), p.582-592
4.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017-09-25, Vol.53 (4), p.557-565
5.
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
by Lamarre, Daniel
Nature, 2003-11-13, Vol.426 (6963), p.186-189
6.
Challenges and successes in developing new therapies for hepatitis C
by Migliaccio, Giovanni
Nature, 2005-08-18, Vol.436 (7053), p.953-960
7.
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
by Skehel, John J
Nature, 2006-09-07, Vol.443 (7107), p.45-49
8.
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
by Marty, Francisco M, Dr
The Lancet infectious diseases, 2011, Vol.11 (4), p.284-292
9.
Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections
by Sezaki, Hitomi
Journal of gastroenterology, 2019-03-22, Vol.54 (10), p.916-927
10.
Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens
by Younossi, Z.
Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.497-520
11.
Potential antivirals and antiviral strategies against SARS coronavirus infections
by De Clercq, Erik
Expert review of anti-infective therapy, 2006-04-01, Vol.4 (2), p.291-302
12.
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity
by Karpinski, Janet
Nature biotechnology, 2016-04, Vol.34 (4), p.401-409
13.
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication
by Debyser, Zeger
Nature Chemical Biology, 2010-06, Vol.6 (6), p.442-448
14.
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
by Kumada, Hiromitsu
Journal of gastroenterology, 2016-11-21, Vol.52 (4), p.520-533
15.
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial
by Low, Jenny G, MPH
The Lancet infectious diseases, 2014, Vol.14 (8), p.706-715
16.
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
by Hoofnagle, Jay H
Nature, 2005-08-18, Vol.436 (7053), p.967-972
17.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and trea...
by Lawitz, Eric, Prof
The Lancet (British edition), 2014, Vol.384 (9956), p.1756-1765
18.
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
by Welsch, Christoph
Gut, 2012-05, Vol.61 (Suppl 1), p.i36-i46
19.
Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment
by Jeon, O.H
Nature medicine, 2017, Vol.23 (6), p.775-781
20.
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR...
by Lawitz, Eric, Prof
The Lancet (British edition), 2014, Vol.383 (9916), p.515-523
